Exact Mass: 402.1167458
Exact Mass Matches: 402.1167458
Found 91 metabolites which its exact mass value is equals to given mass value 402.1167458,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
4-Hydroxy-5-(3',4'-dihydroxyphenyl)-valeric acid-O-glucuronide
C17H22O11 (402.11620619999997)
4-Hydroxy-5-(3,4-dihydroxyphenyl)-valeric acid-O-glucuronide is a conjugate of 4-hydroxy-5-(3,4-dihydroxyphenyl)-valeric acid-O-glucuronide. A glucuronide, also known as glucuronoside, is any substance produced by linking glucuronic acid to another substance via a glycosidic bond. The glucuronides belong to the glycosides. (Wikipedia)
4-Hydroxy-5-(3',5'-dihydroxyphenyl)-valeric acid-O-glucuronide
C17H22O11 (402.11620619999997)
4-Hydroxy-5-(3,5-dihydroxyphenyl)-valeric acid-O-glucuronide is a conjugate of 4-hydroxy-5-(3,5-dihydroxyphenyl)-valeric acid and glucuronide. A glucuronide, also known as glucuronoside, is any substance produced by linking glucuronic acid to another substance via a glycosidic bond. The glucuronides belong to the glycosides. (Wikipedia)
6-[4-(4-carboxy-2-hydroxybutyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
C17H22O11 (402.11620619999997)
6-[4-(4-carboxy-2-hydroxybutyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid is a predicted metabolite generated by BioTransformer¹ that is produced by the metabolism of 5-(3,4-dihydroxyphenyl)-4-hydroxypentanoic acid. It is generated by UDP-glucuronosyltransferase 1-1 (P22309) enzyme via an aromatic-OH-glucuronidation reaction. This aromatic-OH-glucuronidation occurs in humans.
6-[5-(4-carboxy-2-hydroxybutyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
C17H22O11 (402.11620619999997)
6-[5-(4-carboxy-2-hydroxybutyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid is a predicted metabolite generated by BioTransformer¹ that is produced by the metabolism of 5-(3,4-dihydroxyphenyl)-4-hydroxypentanoic acid. It is generated by UDP-glucuronosyltransferase 1-1 (P22309) enzyme via an aromatic-OH-glucuronidation reaction. This aromatic-OH-glucuronidation occurs in humans.
4-Hydroxy-5-(3',5'-dihydroxyphenyl)-valeric acid glucuronide
C17H22O11 (402.11620619999997)
(Z)-6-[(2S,4S,5R)-2-(2-Chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]hex-4-enoic acid
C22H23ClO5 (402.12339380000003)
8-p-Coumaroyl-3,4-dihydro-5,7-dihydroxy-4-phenylcoumarin
Calomelanol I
Calomelanol H
Apodanthoside (Not validated)
C17H22O11 (402.11620619999997)
Annotation level-3
3,3-Ethylidenebis(2-methyl-5-hydroxy-1,4-naphthoquinone)
3,6-Ethylidenebis(2-methyl-5-hydroxy-1,4-naphthoquinone)
1-O,2-O-[(1S,2S)-1-(3-acetyl-2,4,6-trihydroxyphenyl)-3-hydroxypropane-1,2-diyl]-beta-D-glucopyranose|1-O,2-O-[(1S,2S)-1-(3-acetyl-2,4,6-trihydroxyphenyl)-3-hydroxypropane-1,3-diyl]-beta-D-glucopyranose|tomentoside II
C17H22O11 (402.11620619999997)
4-Methoxy-benzoic acid 4-(4-methoxy-phenyl)-2-oxo-2H-chromen-7-yl ester
2,5-diethoxy-4-(p-tolylthio)benzenediazonium tetrafluoroborate
4-[2-(3,4-Dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolinyl)ethyl]benzenesulfonamide
C20H22N2O5S (402.12493620000004)
3-Deoxy-3-fluoro-beta-D-ribofuranose 1-acetate 2,5-dibenzoate
VARESPLADIB sodium
C21H19N2NaO5 (402.11916040000006)
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic Varespladib sodium (LY315920 sodium) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib sodium exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively[1].
5-amino-N-tert-butyl-4-(3-methoxyphenyl)-2-(methylthio)-6-thieno[2,3-d]pyrimidinecarboxamide
C19H22N4O2S2 (402.11841119999997)
4-[[[2-(4-Methoxyphenyl)-3-thiazolidinyl]-sulfanylidenemethyl]amino]benzoic acid ethyl ester
C20H22N2O3S2 (402.10717819999996)
4-(4-methoxyphenyl)-2-oxo-2H-chromen-7-yl 4-methoxybenzoate
5-(2-Ethoxyethyl)-5-[4-(4-fluorophenoxy)phenoxy]pyrimidine-2,4,6(1H,3H,5H)-trione
6-{4-[Hydroxy-(4-nitro-phenoxy)-phosphoryl]-butyrylamino}-hexanoic acid
(E)-6-[2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]hex-4-enoic acid
C22H23ClO5 (402.12339380000003)
4-Hydroxy-5-(3,5-dihydroxyphenyl)-valeric acid glucuronide
C17H22O11 (402.11620619999997)
2-[[Cyclohexyl(oxo)methyl]amino]-4-(3-nitrophenyl)-3-thiophenecarboxylic acid ethyl ester
C20H22N2O5S (402.12493620000004)
4-[[[4-(2-Furanylmethyl)-5-(3-methoxyphenyl)-1,2,4-triazol-3-yl]thio]methyl]benzonitrile
N-[5-[2-(2-methoxyanilino)-4-thiazolyl]-4-methyl-2-thiazolyl]pentanamide
C19H22N4O2S2 (402.11841119999997)
N-[5-[2-(3-methoxyanilino)-4-thiazolyl]-4-methyl-2-thiazolyl]-3-methylbutanamide
C19H22N4O2S2 (402.11841119999997)
6-[5-(3,4-Dihydroxyphenyl)-4-hydroxypentanoyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
C17H22O11 (402.11620619999997)
4-Hydroxy-5-(3,4-dihydroxyphenyl)-valeric acid-O-glucuronide
C17H22O11 (402.11620619999997)
4-Hydroxy-5-(3,5-dihydroxyphenyl)-valeric acid-O-glucuronide
C17H22O11 (402.11620619999997)
6-[2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-4-hexenoic acid
C22H23ClO5 (402.12339380000003)
6-[4-(4-carboxy-2-hydroxybutyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
C17H22O11 (402.11620619999997)
6-[5-(4-carboxy-2-hydroxybutyl)-2-hydroxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
C17H22O11 (402.11620619999997)
Fuzapladib (sodium)
C15H20F3N3NaO3S (402.10751060000007)
Fuzapladib (IS-741) sodium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib sodium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib sodium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site[1][2].
PNU-177864
PNU-177864 is a potent, selective and orally active dopamine D3 receptor antagonist. PNU-177864 is structurally consistent with a cationic amphiphilic agent (CAD) and induces phospholipidosis in vivo. PNU-177864 antischizophrenic activity[1][2].
VU-1545
VU-1545 is a metabotropic glutamate receptor 5 positive allosteric modulator (mGluR5 PAM) with a Ki of 156 nM and an EC50 of 9.6 nM[1].
11-hydroxy-5-methyl-2-[(2r,3s)-2-methyl-3-[(1e)-prop-1-en-1-yl]oxiran-2-yl]-1-oxatetraphene-4,7,12-trione
5-hydroxy-6-[1-(8-hydroxy-3-methyl-1,4-dioxonaphthalen-2-yl)ethyl]-2-methylnaphthalene-1,4-dione
methyl (1s,4as,7s,7as)-7-formyl-7-hydroxy-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7ah-cyclopenta[c]pyran-4-carboxylate
C17H22O11 (402.11620619999997)
3-[(3-chloro-4-hydroxyphenyl)methyl]-4-hydroxy-4-isopropyl-5-[(4-methoxyphenyl)methylidene]oxolan-2-one
C22H23ClO5 (402.12339380000003)
(3r,5as,6s,10ar)-3-benzyl-1,6-dihydroxy-3,10a-bis(methylsulfanyl)-5ah,6h,10h-pyrazino[1,2-a]indol-4-one
C20H22N2O3S2 (402.10717819999996)
(1s,4as,7s,7as)-4-(methoxycarbonyl)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7h,7ah-cyclopenta[c]pyran-7-carboxylic acid
C17H22O11 (402.11620619999997)
4-(methoxycarbonyl)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7h,7ah-cyclopenta[c]pyran-7-carboxylic acid
C17H22O11 (402.11620619999997)
methyl 7-formyl-7-hydroxy-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7ah-cyclopenta[c]pyran-4-carboxylate
C17H22O11 (402.11620619999997)
5-hydroxy-6-[1-(1-hydroxy-6-methyl-5,8-dioxonaphthalen-2-yl)ethyl]-2-methylnaphthalene-1,4-dione
3-benzyl-1,6-dihydroxy-3,10a-bis(methylsulfanyl)-5ah,6h,10h-pyrazino[1,2-a]indol-4-one
C20H22N2O3S2 (402.10717819999996)
(7s,13r)-9-hydroxy-7-(4-hydroxyphenyl)-13-phenyl-4,14-dioxatricyclo[8.4.0.0³,⁸]tetradeca-1,3(8),9-triene-5,11-dione
(3r,4r,5z)-3-[(3-chloro-4-hydroxyphenyl)methyl]-4-hydroxy-4-isopropyl-5-[(4-methoxyphenyl)methylidene]oxolan-2-one
C22H23ClO5 (402.12339380000003)
(7r,13s)-9-hydroxy-13-(4-hydroxyphenyl)-7-phenyl-4,14-dioxatricyclo[8.4.0.0³,⁸]tetradeca-1,3(8),9-triene-5,11-dione
11-hydroxy-5-methyl-2-{2-methyl-3-[(1z)-prop-1-en-1-yl]oxiran-2-yl}-1-oxatetraphene-4,7,12-trione
9-hydroxy-7-(4-hydroxyphenyl)-13-phenyl-4,14-dioxatricyclo[8.4.0.0³,⁸]tetradeca-1,3(8),9-triene-5,11-dione
(1s,4as,7as)-7-(methoxycarbonyl)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylic acid
C17H22O11 (402.11620619999997)
methyl (1s,4ar,7r,7as)-7-formyl-7-hydroxy-1-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7ah-cyclopenta[c]pyran-4-carboxylate
C17H22O11 (402.11620619999997)
5,6,11-trihydroxy-9-methoxy-22-oxahexacyclo[10.10.2.0²,⁷.0⁸,²⁴.0¹⁵,²³.0¹⁶,²¹]tetracosa-2(7),3,5,8(24),9,11,16,18,20-nonaen-13-one
1-{3-[(2s,3s,4ar,6r,7s,8s,8ar)-7,8-dihydroxy-2,6-bis(hydroxymethyl)-hexahydro-2h-pyrano[2,3-b][1,4]dioxin-3-yl]-2,4,6-trihydroxyphenyl}ethanone
C17H22O11 (402.11620619999997)
(1r,15s,23s)-5,6,11-trihydroxy-9-methoxy-22-oxahexacyclo[10.10.2.0²,⁷.0⁸,²⁴.0¹⁵,²³.0¹⁶,²¹]tetracosa-2(7),3,5,8(24),9,11,16,18,20-nonaen-13-one
5-hydroxy-3-[1-(8-hydroxy-3-methyl-1,4-dioxonaphthalen-2-yl)ethyl]-2-methylnaphthalene-1,4-dione
(1s,4as,7as)-7-(methoxycarbonyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylic acid
C17H22O11 (402.11620619999997)
4-(methoxycarbonyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7h,7ah-cyclopenta[c]pyran-7-carboxylic acid
C17H22O11 (402.11620619999997)
11-hydroxy-5-methyl-2-[2-methyl-3-(prop-1-en-1-yl)oxiran-2-yl]-1-oxatetraphene-4,7,12-trione
5-hydroxy-6-[(1s)-1-(8-hydroxy-3-methyl-1,4-dioxonaphthalen-2-yl)ethyl]-2-methylnaphthalene-1,4-dione
(1r,4as,7r,7as)-4-(methoxycarbonyl)-1-{[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,7h,7ah-cyclopenta[c]pyran-7-carboxylic acid
C17H22O11 (402.11620619999997)
7-(methoxycarbonyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylic acid
C17H22O11 (402.11620619999997)